BioNTech SE (NASDAQ:BNTX) has seen 3,998,074 shares traded in the last trading session. The company, currently valued at $14.92 Billion, closed the last trade at $65.8 per share which meant it gained $3.6 on the day or 5.91% during that session. The BNTX stock price is -59.57% off its 52-week high price of $105 and 80.97% above the 52-week low of $12.52. If we look at the company’s 10-day average daily trading volume, we find that it stood at 2.57 Million shares traded. The 3-month trading volume is 1.51 Million shares.
The consensus among analysts is that BioNTech SE (BNTX) is an Overweight stock at the moment, with a recommendation rating of 2.4. None of the analysts rate the stock as a Sell, while none rate it as Overweight. 4 out of 7 have rated it as a Hold, with 3 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.22.
BioNTech SE (NASDAQ:BNTX) trade information
Sporting 5.91% in the green today, the stock has traded in the green over the last five days, with the highest price hit on Monday, Jun 29 when the BNTX stock price touched $71.38- or saw a rise of 7.82%. Year-to-date, BioNTech SE shares have moved 94.21%, while the 5-day performance has seen it change 14.53%. Over the past 30 days, the shares of BioNTech SE (NASDAQ:BNTX) have changed 32.85%. Short interest in the company has seen 3.06 Million shares shorted with days to cover at 2.03.
Wall Street analysts have a consensus price target for the stock at $45.11, which means that the shares’ value could jump -31.44% from current levels. The projected low price target is $28 while the price target rests at a high of $63. In that case, then, we find that the current price level is -4.26% off the targeted high while a plunge would see the stock lose -57.45% from current levels.
BioNTech SE (BNTX) estimates and forecasts
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was +0% over the past 5 years. Earnings growth for 2020 is a modest -300.5% while over the next 5 years, the company’s earnings are expected to increase by 0%.
BioNTech SE (NASDAQ:BNTX)’s Major holders
Insiders own 1.26% of the company shares, while shares held by institutions stand at 4.15% with a share float percentage of 4.2%. Investors are also buoyed by the number of investors in a company, with BioNTech SE having a total of 36 institutions that hold shares in the company. The top two institutional holders are Primecap Management Company with over 2.61 Million shares worth more than $152.55 Million. As of March 30, 2020, Primecap Management Company held 19.79% of shares outstanding.
The other major institutional holder is Artal Group S.A., with the holding of over 2.23 Million shares as of March 30, 2020. The firm’s total holdings are worth over $130.12 Million and represent 16.88% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Horizon Fund-Capital Opportunity Portfolio and Primecap Odyssey Aggressive Growth Fund. As of March 30, 2020, the former fund manager holds about 8.7% shares in the company for having 1147783 shares of worth $67.03 Million while later fund manager owns 945.78 Thousand shares of worth $32.04 Million as of December 30, 2019, which makes it owner of about 7.16% of company’s outstanding stock.